Investor Relations

Delivering value to our shareholders with utmost transparency and timely information.

At Mega Lifesciences public company limited

Investor Relations is responsible for delivering value to our shareholders by communicating all the necessary information on a regular basis.

Investment Highlights

Market leading own consumer health and pharmaceutical brands in fast growing developing markets.

Financial Performance in FY23

Overall operating revenue
THB mn
(Flat YoY)
Gross profit
THB mn
representing 45.2% of operating revenue
SG&A expenses
THB mn
representing 26.7% of operating revenue
Adjusted net profit
THB mn
(up by 1.6% YoY)
Reported net profit
THB mn
(down by 11.0% YoY)

Latest Documents

Read our recent and archived releases, Financial statements, Quarterly results, Presentations, Publications and One Reports.

Financial Statement
Yearly 2023
Download
MD&A
Yearly 2023
Download
Presentation and Webcast
The Opportunity Day Q4/2023
View Webcast Download
Form 56-1 One Report
Form 56-1 One Report 2023
Download
Resource Center

SET Announcements

29 February 2024
Publication of the Invitation to the 2024 Annual General Meeting of Shareholders
Read More
22 February 2024
Resolutions of the Board of Directors' meeting regarding the dividend payment proposal for the year ended December 31, 2023 and the date and agenda items of the Annual General Meeting of Shareholders of 2024 (the "Meeting")
Read More
22 February 2024
Management Discussion and Analysis Yearly Ending 31 Dec 2023
Read More

IR Calendar

02
Apr
2024
The 2024 Annual General Meeting of Shareholders

IR CONTACT

  • Mr. Manoj Gurbuxani (Primary contact)
  • Mr. Francis Rego
  • Ms. Sujintana Boonworapat
  • Ms. Laila Mitnoi (IR Co-ordinator)
  • Mr. Thomas Abraham
  • Mr. Vivek Dhawan
  • investor@megawecare.com
  • +66 2 769 4230